Literature DB >> 33343832

Critical Size Limit of Biodegradable Nanoparticles for Enhanced Lymph Node Trafficking and Paracortex Penetration.

Gregory P Howard1,2, Garima Verma3,4, Xiyu Ke2,5, Winter M Thayer6, Timothy Hamerly4, Victoria K Baxter3,7, John E Lee8, Rhoel R Dinglasan3,4, Hai-Quan Mao1,2,5,9.   

Abstract

Lymph node (LN) targeting through interstitial drainage of nanoparticles (NPs) is an attractive strategy to stimulate a potent immune response, as LNs are the primary site for lymphocyte priming by antigen presenting cells (APCs) and triggering of an adaptive immune response. NP size has been shown to influence the efficiency of LN-targeting and retention after subcutaneous injection. For clinical translation, biodegradable NPs are preferred as carrier for vaccine delivery. However, the selective "size gate" for effective LN-drainage, particularly the kinetics of LN trafficking, is less well defined. This is partly due to the challenge in generating size-controlled NPs from biodegradable polymers in the sub-100-nm range. Here, we report the preparation of three sets of poly(lactic-co-glycolic)-b-poly(ethylene-glycol) (PLGA-b-PEG) NPs with number average diameters of 20-, 40-, and 100-nm and narrow size distributions using flash nanoprecipitation. Using NPs labeled with a near-infrared dye, we showed that 20-nm NPs drain rapidly across proximal and distal LNs following subcutaneous inoculation in mice and are retained in LNs more effectively than NPs with a number average diameter of 40-nm. The drainage of 100-nm NPs was negligible. Furthermore, the 20-nm NPs showed the highest degree of penetration around the paracortex region and had enhanced access to dendritic cells in the LNs. Together, these data confirmed that small, size-controlled PLGA-b-PEG NPs at the lower threshold of about 30-nm are most effective for LN trafficking, retention, and APC uptake after s.c. administration. This report could inform the design of LN-targeted NP carrier for the delivery of therapeutic or prophylactic vaccines.

Entities:  

Keywords:  Antigen presenting cells; Biodegradable nanoparticle; In vivo imaging; Lymph node trafficking; Nanoparticle size; Vaccine delivery

Year:  2019        PMID: 33343832      PMCID: PMC7747954          DOI: 10.1007/s12274-019-2301-3

Source DB:  PubMed          Journal:  Nano Res        ISSN: 1998-0000            Impact factor:   8.897


  33 in total

Review 1.  Liposomes to target the lymphatics by subcutaneous administration.

Authors:  C Oussoren; G Storm
Journal:  Adv Drug Deliv Rev       Date:  2001-08-23       Impact factor: 15.470

2.  Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation.

Authors:  Sachiko Hirosue; Iraklis C Kourtis; André J van der Vlies; Jeffrey A Hubbell; Melody A Swartz
Journal:  Vaccine       Date:  2010-10-08       Impact factor: 3.641

3.  The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node.

Authors:  Michael Sixt; Nobuo Kanazawa; Manuel Selg; Thomas Samson; Gunnel Roos; Dieter P Reinhardt; Reinhard Pabst; Manfred B Lutz; Lydia Sorokin
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

Review 4.  Pathogen recognition and development of particulate vaccines: does size matter?

Authors:  Sue D Xiang; Anja Scholzen; Gabriela Minigo; Cassandra David; Vasso Apostolopoulos; Patricia L Mottram; Magdalena Plebanski
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

5.  Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells.

Authors:  Tri Giang Phan; Irina Grigorova; Takaharu Okada; Jason G Cyster
Journal:  Nat Immunol       Date:  2007-07-29       Impact factor: 25.606

6.  Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.

Authors:  Patricia L Mottram; David Leong; Blessing Crimeen-Irwin; Simone Gloster; Sue D Xiang; Jayesh Meanger; Reena Ghildyal; Nicholas Vardaxis; Magdalena Plebanski
Journal:  Mol Pharm       Date:  2007 Jan-Feb       Impact factor: 4.939

7.  Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration.

Authors:  A Supersaxo; W R Hein; H Steffen
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

8.  Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery.

Authors:  Susan N Thomas; Alex Schudel
Journal:  Curr Opin Chem Eng       Date:  2015-02-01       Impact factor: 5.163

9.  Conduits mediate transport of low-molecular-weight antigen to lymph node follicles.

Authors:  Ramon Roozendaal; Thorsten R Mempel; Lisa A Pitcher; Santiago F Gonzalez; Admar Verschoor; Reina E Mebius; Ulrich H von Andrian; Michael C Carroll
Journal:  Immunity       Date:  2009-01-29       Impact factor: 31.745

10.  Lymph node mapping in the mouse.

Authors:  Maria I Harrell; Brian M Iritani; Alanna Ruddell
Journal:  J Immunol Methods       Date:  2007-12-18       Impact factor: 2.303

View more
  14 in total

Review 1.  Innovations in lymph node targeting nanocarriers.

Authors:  Jihoon Kim; Paul A Archer; Susan N Thomas
Journal:  Semin Immunol       Date:  2021-11-24       Impact factor: 11.130

2.  Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats.

Authors:  Chunhong Dong; Bao-Zhong Wang
Journal:  Adv Nanobiomed Res       Date:  2021-12-07

Review 3.  Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.

Authors:  Shaobo Ruan; Yuanyu Huang; Mei He; Huile Gao
Journal:  Adv Sci (Weinh)       Date:  2022-03-27       Impact factor: 17.521

4.  Flash Technology-Based Self-Assembly in Nanoformulation: From Fabrication to Biomedical Applications.

Authors:  Hanze Hu; Chao Yang; Mingqiang Li; Dan Shao; Hai-Quan Mao; Kam W Leong
Journal:  Mater Today (Kidlington)       Date:  2020-11-02       Impact factor: 31.041

Review 5.  Non-viral COVID-19 vaccine delivery systems.

Authors:  Kyung Soo Park; Xiaoqi Sun; Marisa E Aikins; James J Moon
Journal:  Adv Drug Deliv Rev       Date:  2020-12-17       Impact factor: 17.873

Review 6.  Polymeric nanoparticle vaccines to combat emerging and pandemic threats.

Authors:  David Wibowo; Sytze H T Jorritsma; Zennia Jean Gonzaga; Benjamin Evert; Shuxiong Chen; Bernd H A Rehm
Journal:  Biomaterials       Date:  2020-12-10       Impact factor: 12.479

Review 7.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

Review 8.  Designing spatial and temporal control of vaccine responses.

Authors:  Gillie A Roth; Vittoria C T M Picece; Ben S Ou; Wei Luo; Bali Pulendran; Eric A Appel
Journal:  Nat Rev Mater       Date:  2021-09-28       Impact factor: 76.679

Review 9.  Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.

Authors:  Ting Cai; Huina Liu; Shun Zhang; Jing Hu; Lingxiao Zhang
Journal:  J Nanobiotechnology       Date:  2021-11-25       Impact factor: 10.435

10.  A Versatile and Robust Platform for the Scalable Manufacture of Biomimetic Nanovaccines.

Authors:  Hanze Hu; Chao Yang; Fan Zhang; Mingqiang Li; Zhaoxu Tu; Lizhong Mu; Jianati Dawulieti; Yeh-Hsing Lao; Zixuan Xiao; Huize Yan; Wen Sun; Dan Shao; Kam W Leong
Journal:  Adv Sci (Weinh)       Date:  2021-05-01       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.